Clinical trials: Bacteremia Due to Staphylococcus Aureus
Catheter Bacteremia, Staphylococcus Aureus Infection
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic…
- Trial name
- DALICATH (NCT05117398)
- Testing
- Dalbavancin administration, Standard antibiotic therapy
- Where
- 2 sites in France
- Volunteers
- 406 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bacteremia
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will…
- Trial name
- SABEDTIO (NCT07148960)
- Testing
- Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- West Virginia University
Staphylococcus Aureus Bacteremia
Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57.
- Trial name
- NCT00198302
- Testing
- Aurexis®
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia
Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. Participants were to be randomized (1:1) to daptomycin or comparator, stratified by degree of renal impairment (creatinine clearance [CLcr] 30 …
- Conditions
- Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
- Trial name
- RENSE (NCT01104662)
- Testing
- Vancomycin, Daptomycin, Semi-Synthetic Penicillin
- Where
- 10 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcal Aureus Infection, Staphylococcus Aureus Bacteraemia
Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia
Staphylococcus aureus bacteraemia (SAB) is a major global cause of sepsis-related mortality. Randomised trials of adjunctive antibiotics, including fosfomycin, have not shown consistent benefit, possibly due to inclusion of…
- Trial name
- NCT07155590
- Where
- 2 sites in Spain
- Volunteers
- 369 people
- Sponsor
- Hospital Universitari de Bellvitge
Immune Response To Sepsis, Staphylococcus Aureus Infection
Immune Resolution After Staphylococcus Aureus Bacteremia
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
- Trial name
- NCT01879761
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago
Staphylococcus Aureus Bacteremia
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
Background: Staphylococcus aureus bacteremia (SAB) is frequently encountered in hospitals, with high rates of morbidity and mortality.
- Trial name
- PETCT4SAB (NCT02476487)
- Testing
- FDG PET CT
- Where
- Israel
- Volunteers
- 143 people
- Sponsor
- Rambam Health Care Campus